ISPOR 2026

​

​

​

Advancing Precision Medicine Through AI-Driven Translational Intelligence

 

At NAMina Bio, we are building a new generation of translational platforms designed to bridge the gap between clinical prediction and biological validation.

 

As part of this vision, we contributed to research accepted at ISPOR 2026, focused on the integration of interpretable artificial intelligence and real-world data to improve risk prediction and therapeutic targeting in complex diseases.

 

Featured Work

​

Interpretable AI-Based Risk Profiling of Metabolic Syndrome and Simulated Klotho Modulation Using Real-World NHANES Data (2007–2023)

 

This work leverages large-scale population datasets to:

​

• Identify patient-level risk profiles for metabolic syndrome

• Model the potential impact of Klotho modulation across patient subgroups

• Move beyond correlation toward causally informed predictive insights

 

The study highlights how AI can uncover hidden heterogeneity within patient populations, enabling more precise stratification and intervention strategies.

 

From Data to Decision

​

Traditional approaches in drug development and population health rely heavily on retrospective correlations, often lacking predictive resolution at the individual level.

 

This work demonstrates a shift toward:

​

• Patient-level outcome prediction

• Dynamic risk modeling

• Stratification of responder and non-responder populations

 

At NAMina Bio, we extend these capabilities by translating predictive outputs into biologically meaningful and experimentally actionable insights.

 

Translational Interpretation Framework™

 

A central component of our approach is the Translational Interpretation Framework™, which enables:

 

• Conversion of AI-generated predictions into mechanistic hypotheses

• Identification of targetable pathways and biomarkers

• Design of human-relevant validation strategies

 

This framework ensures that predictive insights are not only statistically robust, but also biologically grounded and clinically actionable.

 

Bridging AI and Human-Relevant Biology

​

NAMina Bio integrates advanced experimental systems to support next-phase validation:

​

• Patient-derived organoids

• 3D bioprinted tissue models

• Organ-on-chip and dynamic culture systems

• Multi-omics integration

 

This enables a continuous loop:

Prediction → Interpretation → Validation → Refinement

 

 

Clinical Relevance and Future Direction

 

The ISPOR 2026 work provides a strong foundation for expanding into:

​

• Clinically anchored validation workflows

• Prospective patient stratification strategies

• AI-guided experimental design

• Integration of real-world and experimental datasets

 

NAMina Bio is actively developing a Clinical Integration Layer, enabling access to patient cohorts and diagnostic pipelines to further strengthen the link between prediction and real-world outcomes.

 

Toward Decision-Grade Translational Intelligence

​

This work reflects a broader shift in the field:

 

From data generation → to prediction → to decision-grade translational insight

 

By combining AI-driven modeling with human-relevant experimental systems, NAMina Bio is contributing to a more predictive, efficient, and human-centered approach to drug development and precision medicine.

 

About NAMina Bio

 

NAMina Bio is a translational intelligence platform integrating advanced in vitro systems, real-world data, and interpretable AI to generate human-relevant, decision-ready insights for drug development and disease modeling.